Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities?

Naresh Poondla1,#, Arun Pandian Chandrasekaran1,#, Kye-Seong Kim1,2,* & Suresh Ramakrishna1,2,*

1Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, 2College of Medicine, Hanyang University, Seoul 04763, Korea

Cancer remains a life-threatening disease and accounts for the major mortality rates worldwide. The practice of using biomarkers for early detection, staging, and personalized therapy may increase cancer patients' survival. Deubiquitinating enzymes (DUBs) are a family of proteases that remove ubiquitin tags from proteins of interest undergoing proteasomal degradation. DUBs play several functional roles other than deubiquitination. One of the important roles of DUBs is regulation of tumor progression. Several reports have suggested that the DUB family members were highly-elevated in various cancer cells and tissues in different stages of cancer. These findings suggest that the DUBs could be used as drug targets in cancer therapeutics. In this review, we recapitulate the role of the DUB family members, including ubiquitin-specific protease, otubain protease, and important candidates from other family members. Our aim was to better understand the connection between DUB expression profiles and cancers to allow researchers to design inhibitors or gene therapies to improve diagnosis and prognosis of cancers. [BMB Reports 2019; 52(3): 181-189]

INTRODUCTION

Cancer is one of the major diseases causing death globally, accounting for 8.2 million deaths in 2012 (1). Recent advances in molecular and cellular biology have played important roles in understanding cancer and breakthroughs that have been being translated into therapy. Because of these recent developments, genes that are involved in cancer are being unraveled (2, 3). Most of the known cancer genes were originally identified by genetic evidence. A protein that is encoded by a cancer gene typically regulates cell proliferation and differentiation and eventually leads to cell death or apoptosis. Mutations that lead to oncogenesis typically occur in genes that mediate DNA repair mechanisms (4).

Ubiquitin proteasome pathway

The post-translational attachment of ubiquitin is a modification that can determine a protein’s fate. While ubiquitin itself is a small conserved protein, its covalent conjugation to protein substrates and to other ubiquitin molecules is a tightly-controlled process involving complex cellular machinery. Perhaps the most prominent and well-known function of ubiquitin is to target a protein for degradation by the 26S proteasome. Degradation can be accomplished via an isopeptide bond formation between the carboxy-terminal glycine (Gly) site on the ubiquitin and an ε-amino group of the lysine (Lys) side chains of a protein substrate. The ubiquitin-substrate system is further diversified via the process of polyubiquitination, during which a ubiquitin molecule’s C-terminal Gly is conjugated with one of the seven Lys residues on another ubiquitin (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, or Lys63) or with the N-terminus to form linear chains.

The ubiquitin-proteasome protein degradation pathway is comprised of ubiquitin, a three-enzyme ubiquitination complex, the intracellular protein ubiquitination targets, and the proteasome that is the organelle of protein degradation, as well as ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3).

Deubiquitinating enzymes

Deubiquitinating enzymes (DUBs) are proteases that reverse protein ubiquitination, a process which is significant for normal homeostasis. DUBs have four distinct mechanisms of action: 1) processing of ubiquitin precursors, 2) recycling of ubiquitin molecules during ubiquitination, 3) cleavage of polyubiquitin chains, and 4) reversal of ubiquitin conjugation (Fig. 1). DUBs regulate several cellular functions, including proteasome-dependent and lysosome-dependent proteolysis, gene expression, cell cycle progression, chromosome segrega-
DUBs as cancer biomarkers
Naresh Poondla, et al.

Fig. 1. Various catalytic mechanisms exhibited by DUBs. DUBs can unknot ubiquitin conjugation by cleaving the bond between ubiquitin molecules and ubiquitin-target complexes, editing ubiquitin chains to remove one or more ubiquitin molecules, and finally, recycling of ubiquitin molecules in the ubiquitin-proteasome pathway.

Approximately 100 DUBs are encoded in the human genome (10). Based on the organization of the catalytic domain, DUBs are classified into distinct families, the vast majority of which are cysteine proteases. These include ubiquitin-specific proteases (USPs), ubiquitin C-terminal hydrolases (UCHs), ovarian tumor proteases (OTUs), Machado-Joseph disease proteases (MJDs), Jab1/Mov34/Mpr1 (JAMM) metalloproteases, and the recently-discovered MIU-containing novel DUB family, (MINDY) proteases (11).

UBIQUITIN-SPECIFIC PROTEASE FAMILY

USP2
USP2a, an isof orm of USP2, is an androgen-regulated DUB that deubiquitinates the antiapoptotic proteins such as fatty acid synthase, Mdm2, and MdmX (12). USP2a expression is increased in glioma cells compared to normal brain tissues, which suggests that USP2a may correlate with malignant glioma progression, and therefore may be an effective marker for glioma prognosis (13). Furthermore, USP2 plays a role in tumor metastasis by modulating the activity or expression of MMP2, suggesting its use as a potential breast cancer marker (13).

USP4
USP4 has been strongly implicated in the regulation of tumor metastasis in breast cancer (14), liver cancer (15), and colorectal cancer (16). USP4 is significantly increased in melanoma and plays an oncogenic role by simultaneously inhibiting stress-induced cell apoptosis and promoting tumor metastasis (17). USP4 is an important protein that facilitates hepatocellular carcinoma (HCC) progression by stabilizing CYP2A through deubiquitination and activating MAPK/CrkII signaling pathways, indicating that USP4 may act as a novel marker to predict prognosis and present a therapeutic opportunity for HCC (18). In breast cancer, USP4 promotes the migration and invasion of breast cancer cells via RLX-mediated TGF-β/Smad2/MMP-9 pathways, providing an attractive target for breast cancer therapy (19). The above results suggested that overexpression of USP4 in various cancers is due to the stabilization of other oncogenes in the respective cancer types. Thus, targeting USP4 as a biomarker could be useful for the early diagnosis of cancer.

USP5
USP5 acts as an exopeptidase that hydrolyzes isopeptide bonds in poly-ubiquitin from their free carboxy-terminal ends to produce monoubiquitin (20). USP5 knockdown suppressed cell proliferation, migration, and drug resistance and induced apoptosis, while USP5 overexpression promoted colony formation, migration, drug resistance, and tumorigenesis (21). USP5 plays a critical role in hepatocarcinogenesis through inactivation of the p14-p53 signaling pathway contributing to tumorigenesis and drug resistance, which provides a clue that USP5 could be a potential therapeutic target for HCC (22). In pancreatic cancer, USP5 plays a critical role in tumorigenesis and progression by stabilizing the FoxM1 protein, showing therapeutic potential against pancreatic cancer (23).

USP7
USP7, also known as herpes-associated ubiquitin-specific protease (HAUSP), was originally identified as an ubiquitin-specific protease that binds to a viral-encoded protein, called Vmw110 (24). HAUSP protein can bind to the herpes simplex virus type 1 (HSV-1) regulatory protein, which is known as infected cell polypeptide (ICPO). In epithelial ovarian cancer (EOC), USP7 and MARCH7 proteins are differentially expressed and the combination of USP7 and MARCH7 expression may function as promising biomarkers for EOC prognosis (25). HCC is one of the most dominant cancer types in the world. High expression of USP7 mRNA and protein levels in HCC tissues compared to normal liver samples has been reported (26). Cell-based assays have suggested that USP7 expression confers cell proliferation, migration, and invasion capabilities. These data suggest that USP7 could be a novel independent prognostic marker for HCC. Recently, a study suggested that USP7 deubiquitinates Ki-67, and thereby promotes cell proliferation in non-small-cell lung cancer (NSCLC) (27). Here, both Ki-67 and USP7 were expressed in NSCLC cells. Statistical data revealed a strong correlation between USP7 and Ki-67 levels. In contrast, siRNA targeting
USP7 increased the ubiquitination of Ki-67 and led to delayed tumor growth. The above evidence suggests that USP7 could be an important therapeutic target in various cancer types.

**USP8**
USP8 belongs to the USP superfamily of DUBs targeting several substrates (28), including smoothened (29), frizzled (30), neuregulin receptor degradation protein-1, and receptor tyrosine kinase. Recently, the expression profile of USP8 in cervical squamous cell carcinoma (CSCC) has been studied (31). USP8 was upregulated in CSCC tissue samples compared to non-cancerous cervical tissues. Also, high expression of USP8 was associated with tumor stage and was recognized as an independent prognostic marker for CSCC. Elevated levels of USP8 led to cell proliferation, migration, and invasion of CSCC cell lines. Thus, USP8 could be a therapeutic and diagnostic target in CSCC patients.

**USP10**
USP10, also known as UBPO, is a protein consisting of 798 amino acids and was originally discovered as a DUB that interacts with the Ras-GAP SH3 domain-binding protein (32). Increased USP10 expression has been detected in some breast cancer and glioblastoma samples. Overexpression of USP10 has been associated with poor prognosis for glioblastoma multiforme patients, while decreased USP10 has been observed in gastric cancer tissues, and its downregulation has been associated with invasion, metastasis, and poor prognosis of gastric cancer. Current studies have also shown that USP10 suppressed proliferation and growth of pancreatic cancer cells.

Therefore, USP10, as a novel DUB, has a crucial role in various pathological processes of tumors. In gastric cancer (GC), clinical samples and cell lines showed low-level expression of USP10, and negative USP10 expression was associated with a marked propensity toward gastric wall invasion, lymph node metastasis, highly malignant biological behavior, and poor survival. USP10 identification in GC can potentially serve as a new prognostic indicator predicting the treatment outcome for GC patients.

**USP22**
USP22 is a novel DUB that has been related to cell cycle progression, therapy resistance, and metastasis. The expression frequency of USP22 was extremely high in HCC compared to normal liver tissues (31). Elevated levels of USP22 represented poor HCC patient survival and have also been associated with greater mortality in patients with advanced tumor stages, shown by Kaplan-Meier analysis. As revealed by multivariate analyses, USP22 is a self-regulating prognostic marker in HCC. Several other researchers have reported that USP22 was overexpressed in salivary duct carcinoma (33) and esophageal squamous cell carcinoma (34). The above findings indicate that high USP22 expression might be an important factor in tumor progression and may serve as an independent molecular marker.

**USP32**
USP32 is a highly-conserved and uncharacterized gene, located on the 17q23.1-17q23.2 chromosomal band (35). USP32 was present in 22% of primary breast cancer tumors...
compared to non-cancerous mammary tissues, and 50% of breast cancer cell lines. Endogenously, USP32 was highly-elevated in the MCF7 cell line, and no mutation was detected in this cell line, indicating that the wild-type gene was overexpressed. Additionally, USP32 has a role in human small cell lung cancer (SCLC) (36). USP32 is highly-expressed in SCLC tissue samples compared to normal tissues. During the disease aggravation stage, USP32 has been positively correlated with SCLC expression. On the other hand, downregulation of USP32 in vitro caused reduced migration and proliferation rates of SCLC cells. Also, this downregulation arrested the cells at the G0/G1 phase by elevating p21 and decreasing CDK4-cyclin D1 complex levels. Cleaved caspase-3 and cleaved-PARP were activated when the USP32 gene was silenced, eventually leading to apoptosis by altering the epithelial-mesenchymal transition. Overall, USP32 could be a potential target for breast and lung cancers.

**OTUBAIN PROTEASE FAMILY**

**OTUB1**
The OTU domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) belongs to the OTU DUB family and is reported to be involved in various malignancies (37-40). Recently, the role of OTUB1 in human gliomas has been elucidated (41). Immunoblot and immunohistochemical experiments validated that glioma tissues overexpress OTUB1 genes and statistical studies showed that the expression pattern of OTUB1 was highly-linked to the WHO grades of the gliomas. On the other hand, downregulation of OTUB1 was linked to poor migration and also elevated EMT-related protein E-cadherin expression. Thus, OTUB1 might be involved in the regulation of ECM stability. The above results suggested that OTUB1 could be an important cancer marker in gliomas and other malignancies and could be a potential target for successful cancer therapy.

**A20**
A20 is a DUB that was originally found to be involved in autoimmunity and inflammation (42). However, a recent study proposed that A20 is highly involved in cancer metastasis (43). Here, A20 overexpression leads to metastasis of basal-like breast cancer by monoubiquitinating Snail1. In human basal-like breast cancers, A20 was significantly overexpressed and accounted for cancer metastasis. Additionally, A20 mediates TGF-β1-induced EMT of breast cancers by monoubiquitylating Snail1. Reports also suggested that the transient knockdown of A20 displayed decreased lung cancer metastasis in orthotopic breast cancer models and mouse xenografts.

### Table 1. DUBs and their inhibitors in cancer therapeutics

<table>
<thead>
<tr>
<th>DUB</th>
<th>Inhibitor(s)</th>
<th>Disease Indication</th>
<th>Stage of development</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>USP1</td>
<td>ML323, Pimozide</td>
<td>Oncology</td>
<td>Preclinical</td>
<td>(50)</td>
</tr>
<tr>
<td>USP2</td>
<td>ML364</td>
<td>Inflammation</td>
<td>Preclinical</td>
<td>(50)</td>
</tr>
<tr>
<td>USP4</td>
<td>Vialinin A</td>
<td>Inflammation and oncology</td>
<td>Preclinical</td>
<td>(51, 52)</td>
</tr>
<tr>
<td>USP5</td>
<td>WP1130</td>
<td></td>
<td>Preclinical</td>
<td>(53)</td>
</tr>
<tr>
<td>USP7</td>
<td>ADC-01, ADC-03</td>
<td>Oncology, Immuno-oncology</td>
<td>Preclinical</td>
<td>(54)</td>
</tr>
<tr>
<td></td>
<td>HBX41108</td>
<td>Oncology, Immuno-oncology</td>
<td>Preclinical</td>
<td>(55)</td>
</tr>
<tr>
<td></td>
<td>PS091</td>
<td>Oncology, Immuno-oncology</td>
<td>Preclinical</td>
<td>(56)</td>
</tr>
<tr>
<td></td>
<td>P22077</td>
<td>Oncology, Immuno-oncology</td>
<td>Preclinical</td>
<td>(56)</td>
</tr>
<tr>
<td>USP8</td>
<td>9-Ethoxyimino-9H-indeno (1,2-b) pyrazine-2,3-dicarbonitrile</td>
<td>Oncology</td>
<td>Preclinical</td>
<td>(56)</td>
</tr>
<tr>
<td>USP9X</td>
<td>WP1130</td>
<td>Oncology</td>
<td>Preclinical</td>
<td>(57)</td>
</tr>
<tr>
<td>USP10 and USP13</td>
<td>Sputain 1</td>
<td>Inflammation</td>
<td>Preclinical</td>
<td>(57)</td>
</tr>
<tr>
<td>USP11</td>
<td>Mitoxantrone</td>
<td>Oncology</td>
<td>Preclinical</td>
<td>(58)</td>
</tr>
<tr>
<td>USP14</td>
<td>1U1, b-AP15, VLX1370, wp1130</td>
<td>Neurodegeneration</td>
<td>Preclinical</td>
<td>(59)</td>
</tr>
<tr>
<td>USP20</td>
<td>GSK2643943A</td>
<td>Oncology</td>
<td>Preclinical</td>
<td>(60)</td>
</tr>
<tr>
<td>USP30</td>
<td>15-oxospiramictactone</td>
<td>Neurodegeneration</td>
<td>Preclinical</td>
<td>(61)</td>
</tr>
<tr>
<td>USP47</td>
<td>PS091</td>
<td>Cancer</td>
<td>Preclinical</td>
<td>(56)</td>
</tr>
<tr>
<td>UCH37</td>
<td>WP1130</td>
<td>Cancer</td>
<td>Preclinical</td>
<td>(57)</td>
</tr>
<tr>
<td>UCHL5</td>
<td>b-AP15</td>
<td>Neurology</td>
<td>Preclinical</td>
<td>(62)</td>
</tr>
<tr>
<td>UCHL1</td>
<td>LDN-57444</td>
<td>Cancer</td>
<td>Preclinical</td>
<td>(63)</td>
</tr>
<tr>
<td>UCHL3</td>
<td>LDN-57444</td>
<td>Cancer</td>
<td>Preclinical</td>
<td>(64)</td>
</tr>
<tr>
<td>UCHL5</td>
<td>TCID, b-AP15</td>
<td>Cancer</td>
<td>Preclinical</td>
<td>(62, 65)</td>
</tr>
<tr>
<td>UCH37</td>
<td>WP1130</td>
<td>Cancer</td>
<td>Preclinical</td>
<td>(57)</td>
</tr>
</tbody>
</table>
### Table 2. DUBs expressed in various types of cancer

<table>
<thead>
<tr>
<th>Disease</th>
<th>DUB Reference(s)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gliomas</td>
<td>USP2a, USP22, USP44, BAP1, OTUB1</td>
<td>(41, 66, 67)</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>USP2, USP22, USP37</td>
<td>(68, 69)</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>USP4, USP5, USP11, USP22, UCHL1, A20, OTUB1</td>
<td>(70, 71)</td>
</tr>
<tr>
<td>Esophageal cancer</td>
<td>USP4</td>
<td>(72)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>USP4</td>
<td>(72)</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>USP5</td>
<td>(72)</td>
</tr>
<tr>
<td>Epithelial ovarian cancer</td>
<td>USP7</td>
<td>(72)</td>
</tr>
<tr>
<td>Lung adenocarcinoma</td>
<td>USP8</td>
<td>(73, 74)</td>
</tr>
<tr>
<td>Gastric carcinoma</td>
<td>USP10</td>
<td>(75)</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>USP14</td>
<td>(75)</td>
</tr>
<tr>
<td>Non-small cell lung carcinoma</td>
<td>USP17, USP22, OTUD7B, OTUD6B</td>
<td>(76, 77)</td>
</tr>
<tr>
<td>Renal clear cell carcinoma</td>
<td>USP21</td>
<td>(78)</td>
</tr>
<tr>
<td>Muscle invasive bladder cancer</td>
<td>USP18</td>
<td>(79)</td>
</tr>
<tr>
<td>Cervical cancer</td>
<td>USP22</td>
<td>(80)</td>
</tr>
<tr>
<td>Oral squamous cell carcinoma</td>
<td>USP22</td>
<td>(81)</td>
</tr>
<tr>
<td>Papillary thyroid carcinoma</td>
<td>USP22, USP33</td>
<td>(82, 83)</td>
</tr>
<tr>
<td>Salivary duct carcinoma</td>
<td>USP22</td>
<td>(83)</td>
</tr>
<tr>
<td>Esophageal squamous cell carcinoma</td>
<td>USP22</td>
<td>(34)</td>
</tr>
<tr>
<td>Salivary adenoid cystic carcinoma</td>
<td>USP22</td>
<td>(34)</td>
</tr>
<tr>
<td>Bladder cancer</td>
<td>USP28</td>
<td>(84)</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>USP33, OTUB1, MYSM1</td>
<td>(85, 86)</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>USP39</td>
<td>(87)</td>
</tr>
<tr>
<td>Malignant peritoneal mesothelioma</td>
<td>BAP1</td>
<td>(88)</td>
</tr>
<tr>
<td>Triple-negative breast cancer</td>
<td>OTUD7B</td>
<td>(89)</td>
</tr>
<tr>
<td>Pancreatic ductal adenocarcinoma</td>
<td>UCHL5</td>
<td>(90)</td>
</tr>
<tr>
<td>Gastric cardiac adenocarcinoma</td>
<td>UCHL1</td>
<td>(91)</td>
</tr>
<tr>
<td>Cholangiocarcinoma</td>
<td>UCHL1</td>
<td>(91)</td>
</tr>
<tr>
<td>Aggressive multiple myeloma</td>
<td>UCHL1</td>
<td>(92)</td>
</tr>
<tr>
<td>Neuronal apoptosis</td>
<td>USP4, UCHL1</td>
<td>(93, 94)</td>
</tr>
<tr>
<td>Cardiac hypertrophy</td>
<td>USP4</td>
<td>(95)</td>
</tr>
<tr>
<td>Aneurysmal bone cyst</td>
<td>USP6</td>
<td>(96)</td>
</tr>
<tr>
<td>Pancreatic beta cells</td>
<td>UCHL1</td>
<td>(97)</td>
</tr>
<tr>
<td>Aneurysmal subarachnoid hemorrhage</td>
<td>UCHL1</td>
<td>(98)</td>
</tr>
<tr>
<td>Neuronal biomarker</td>
<td>UCHL1</td>
<td>(99)</td>
</tr>
<tr>
<td>Traumatic brain injury</td>
<td>UCHL1</td>
<td>(100)</td>
</tr>
<tr>
<td>Pancreatic neuroendocrine tumors</td>
<td>UCHL1</td>
<td></td>
</tr>
</tbody>
</table>
The authors have no conflicting interests.

Korean government (MSIP and MOHW) (2017M3A9E4048172). National Research Foundation (NRF) and funded by the and Bio and Medical Technology Development Program of the (NRF), which is funded by the Ministry of Education (2017R1A2B2008727, 2018M3A9H3022412 and 2017M3A9B3061830) (NRF), which is funded by the Ministry of Education (2017R1A2B2008727, 2018M3A9H3022412 and 2017M3A9B3061830)

ACKNOWLEDGEMENTS

This review delivers a comprehensive report of the DUBs for cancer diagnosis and prognosis. Recent developments of cancer therapies and the promptness of their application to clinical use for various tumors validate the prospects of exploiting DUBs as targets for drug development. The expression profiles of several DUBs in different cancer types are discussed in Table 2. Moreover, these DUBs exert their function through binding to their proteins, which can be targeted. In other cases, the DUB itself seems to be an excellent drug target. More detailed information on the roles, localization, regulation, and substrates of DUBs will help researchers understand their roles in oncogenesis and clinical applications of their inhibitors. Enhanced improvement in small molecule pharmacological development against DUBs will permit greater success in the treatment of cancer and other deadly diseases.

CONFICTS OF INTEREST

The authors have no conflicting interests.

REFERENCES

18. Li T, Yan B, Ma Y et al (2018) Ubiquitin-specific aldehyde (Uba) and ubiquitin vinyl sulfone (UbVS) (48). Due to their high molecular weights, peptidic nature, and lack of specificity, these compounds were not pharmacologically sustainable (48). The UCH family of proteins is involved in deubiquitination by removing ubiquitin from C-terminal adducts (48). Hence, researchers have made an effort to design their inhibitors and ended up with an isatin O-acyl oximes series (48). They are competitive and capable of directly targeting the active site with minimal IC50 values. Basically, UCH-L1 decreases cell proliferation in neuroblastoma cells; when this inhibitor is applied, cell proliferation is elevated. Thus, the data support the anti-proliferative nature of UCH-L1 proteins. A novel proteasome-inhibitory compound has been synthesized, called b-AP15 (49). The b-AP15 small molecule specifically inhibits USP14 and UCHL5 which are associated with 19S RP. Additionally, the compound b-AP15 showed effective anti-cancer responses against other refractory cancer types. Inhibitors targeting other important DUBs are described in Table 1.

CONCLUSION

This review delivers a comprehensive report of the DUBs for cancer diagnosis and prognosis. Recent developments of cancer therapies and the promptness of their application to clinical use for various tumors validate the prospects of exploiting DUBs as targets for drug development. The expression profiles of several DUBs in different cancer types are discussed in Table 2. Moreover, these DUBs exert their function through binding to their proteins, which can be targeted. In other cases, the DUB itself seems to be an excellent drug target. More detailed information on the roles, localization, regulation, and substrates of DUBs will help researchers understand their roles in oncogenesis and clinical applications of their inhibitors. Enhanced improvement in small molecule pharmacological development against DUBs will permit greater success in the treatment of cancer and other deadly diseases.
protease 4 promotes hepatocellular carcinoma progression via cyclophillin A stabilization and deubiquitination. Cell Death Dis 9, 148-165


37. BMBS as cancer biomarkers

http://bmbreports.org BMB Reports 187

is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 138, 1291-1297


40. OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination. EMBO Mol Med 8, 288-303

41. Deubiquitinase inhibitor is associated with oxidative stress. Antioxid Redox Signal 21, 2271-2285


43. Cancer Ther 147, 32-54


48. BMBS as cancer biomarkers

http://bmbreports.org BMB Reports 187

is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 138, 1291-1297


DUBs as cancer biomarkers

Naresh Poondla, et al.

Biol 35, 4017-4022


